Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CDIO vs RENX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CDIO Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 7–1 Matrix Metrics)

CDIO Overall Winner 6-Pillar Tally: CDIO 3 – 0 RENX (3 Tie) Matrix Metrics: CDIO 7 – 1 RENX

As of Nov 20, 2026, Cardio Diagnostics Holdings Inc. (CDIO) is the stronger overall head-to-head candidate over RENX (RENX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CDIO carries a Unified Composite Score of 47.2/100 (HOLD) at $1.60 (N/M Forward P/E, -42649.8% operating margin), whereas RENX carries 44.0/100 (HOLD) at $0.74 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: CDIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.6); meanwhile RENX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CDIO vs RENX
CDIO NASDAQ Head-to-Head Winner
Cardio Diagnostics Holdings Inc. Common stock
In Vitro & In Vivo Diagnostic Substances
$1.60
-3.03% 1D
Market Cap $4.9M
TTM Revenue $15,185
Forward P/E N/M
Beta / 30D Vol 1.36β · 56% Vol
Unified Composite Score
47.2 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 39
RSI-14: 38.6 · SMA20: $1.73 · SMA50: $1.82
RENX US Equity
RENX
Institutional Equity
$0.74
-23.09% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -17.85β · 161% Vol
Unified Composite Score
44.0 / 100 HOLD
Tech 33.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.4%), weak momentum, RSI 32
RSI-14: 31.6 · SMA20: $1.05 · SMA50: $1.49

6-Pillar Scorecard Institutional Category Breakdown (CDIO 3 – 0 RENX)

Columns: Metric · CDIO · RENX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CDIO
Revenue Growth (YoY) +25.7% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $15,185 N/A
Market Cap $4.9M N/A
3. Profitability & Quality CDIO
Gross Margin 100.0% N/A
Operating Margin -42649.8% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -93.5% N/A
4. Balance Sheet & Cash Flow CDIO
Cash Generation (TTM) -$6.3M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $6.5M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CDIO (7) vs RENX (1)
Institutional Metric CDIO RENX Criterion Row Edge
Market Capitalization
Scale
$4.9M N/A Larger Scale CDIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+25.7% N/A Higher Growth CDIO
Operating Margin (TTM)
Profitability
-42649.8% N/A Higher Margin CDIO
Net Profit Margin
Profitability
0.0% N/A Higher Margin CDIO
Return on Equity (ROE)
Capital Efficiency
-93.5% N/A Higher ROE CDIO
52-Week Range Position
Momentum
9% ($1–$8) 19% ($0–$3) Stronger Trend RENX
Beta / 30D Volatility
Risk Regime
1.36β · 56% Vol -17.85β · 161% Vol Lower Realized Risk CDIO
Unified Institutional Score
Composite Signal
47.2 / 100 (HOLD) 44.0 / 100 (HOLD) Higher Composite CDIO
Trailing 12M Revenue (USD)
Operating Scale
$15,185 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.3M ($6.5M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDIO +42.05 pp
CDIO: -6.16% · RENX: -48.21%
3M Horizon CDIO +45.79 pp
CDIO: -16.88% · RENX: -62.67%
6M Horizon CDIO +51.93 pp
CDIO: -0.62% · RENX: -52.55%
1Y Horizon RENX +212.13 pp
CDIO: -48.55% · RENX: +163.58%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CDIO vs RENX. Trailing 12-month operating profitability (CDIO -42649.8% vs RENX N/A) and valuation multiples (CDIO N/M vs RENX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CDIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$15,185
Gross Margin100.0%
Op. Margin-42649.8%
ROE / Fwd P/E-93.5% · N/M
RENX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CDIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RENX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RENX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CDIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.9M market capitalization and -42649.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RENX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CDIO vs RENX Key Questions & Quantitative Answers

As of Nov 20, 2026, Cardio Diagnostics Holdings Inc. (CDIO) is the stronger overall head-to-head candidate over RENX (RENX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CDIO carries a Unified Composite Score of 47.2/100 (HOLD) at $1.60 (N/M Forward P/E, -42649.8% operating margin), whereas RENX carries 44.0/100 (HOLD) at $0.74 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: CDIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.6); meanwhile RENX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CDIO leads the Growth & Scale pillar: CDIO posts +25.7% YoY revenue growth and +0.0% YoY earnings growth on $15,185 TTM revenue (100.0% gross margin, -42649.8% operating margin), compared with RENX at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, CDIO generates $15,185 in USD-normalized revenue versus N/A for RENX. In operating R&D and SG&A reinvestment, CDIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RENX.

CDIO and RENX trade at balanced relative valuation multiples. CDIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas RENX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDIO (-93.5% ROE) versus RENX (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, CDIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.36β · 56% Vol realized risk). By comparison, RENX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-17.85β · 161% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.